Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) primarily focuses on taurine as a food additive, mainly applied in the food and beverage industry, with its subsidiary Yong'an Health offering products suitable for fatigue relief [1] Group 1 - The main product of the company, taurine, is utilized as a food additive [1] - The application of taurine is primarily in the food and beverage sectors [1] - Yong'an Health, a subsidiary, has its own brand products aimed at individuals seeking fatigue relief [1] Group 2 - The company and its subsidiaries do not directly supply related products to the military [1]

证券日报网讯12月1日，永安药业（002365）在互动平台回答投资者提问时表示，截至2025年11月20 日，公司股东人数为53994户。 ...

（文章来源：证券日报） 证券日报网讯永安药业11月24日在互动平台回答投资者提问时表示，子公司永安康健易加能自有品牌产 品线下渠道正按计划稳步推进中。永安康健对线上和线下渠道实行了差异化的产品战略，线上主推"易 加能"自有品牌产品，线下则主推"牛番"自有品牌产品，目前"牛番"自有品牌产品已入驻云南健之佳连 锁药店。 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-67 潜江永安药业股份有限公司 关于购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日、2025 年 6 月 24 日分别召开了第七届董事会第六次临时会议及 2024 年年度股东会，审 议通过了《关于使用自有资金进行委托理财的议案》，同意公司及子公司总计使 用最高额度不超过（含）人民币 7.5 亿元的自有资金进行委托理财。上述额度 可滚动使用，有效期自股东会审议通过之日起不超过 12 个月，并授权公司管理 层具体实施相关事宜。公司根据上述决议，择机购买了相关理财产品，现将有关 情况公告如下： 一、理财产品的主要情况 （一）2025 年 11 月 17 日，公司出资 3000 万元，向中国中金财富证券有限 公司（以下简称"中金财富"）购买理财产品，具体情况如下： 3、预计到期年化收益率：2.3%+超额收益 4、产品收益起始日：2025 年 11 月 19 日 5、产品到期日：90 个自然日后每个开放日 ...

Core Viewpoint - The company announced the absorption merger of its associate company Huanggang Daily Chemical by its wholly-owned subsidiary Tianan Daily Chemical, which will lead to a change in investment targets and related transactions [1][4][5]. Group 1: Merger Details - The merger will not involve cash payments, and shareholders of Huanggang Daily Chemical will exchange their shares for equity in Tianan Daily Chemical on a pro-rata basis [2][5]. - After the merger, Huanggang Daily Chemical will be dissolved, and all its assets, liabilities, and equity will be inherited by Tianan Daily Chemical [5][10]. - The company's previous investment of 30 million yuan in Huanggang Daily Chemical will convert into a direct investment in Tianan Daily Chemical, maintaining a shareholding ratio of 6.5217% [2][5]. Group 2: Board Meeting and Approval - The board meeting to discuss the merger was held on November 11, 2025, with all seven directors participating, and the proposal was approved with five votes in favor and two abstentions [1][6]. - The independent directors had previously reviewed and approved the proposal before it was submitted to the board [3][6]. Group 3: Purpose and Impact - The merger aims to optimize the management structure of the associate company, reduce management costs, and improve decision-making efficiency, aligning with the company's overall development strategy [13]. - The financial statements of Tianan Daily Chemical will not be included in the company's consolidated financial statements post-merger, indicating no significant impact on the company's financial status or overall business development [13]. Group 4: Related Transactions - From January to October 2025, the total amount of related transactions between the company and its associated entities was approximately 28.19 million yuan, with 24.52 million yuan specifically involving Tianan Daily Chemical and Huanggang Daily Chemical [13].

Core Viewpoint - Yong'an Pharmaceutical announced the absorption merger of its affiliated company Huanggang Daily Chemical by its wholly-owned subsidiary Hubei Tian'an Daily Chemical, resulting in a change of investment targets and related party transactions [1] Group 1: Merger Details - The merger involves Huanggang Daily Chemical being absorbed by Hubei Tian'an Daily Chemical, with Tian'an Daily Chemical as the surviving entity and Huanggang Daily Chemical being dissolved [1] - The merger will not involve cash payments; shareholders of Huanggang Daily Chemical will exchange their shares for equity in Tian'an Daily Chemical on a pro-rata basis [1] - After the merger, the original investment of 30 million yuan in Huanggang Daily Chemical will convert to a direct investment in Tian'an Daily Chemical, maintaining a shareholding ratio of 6.5217% [1] Group 2: Related Party Transactions - The transaction constitutes a related party transaction as the controlling shareholder and actual controller, Mr. Chen Yong, is also the actual controller of Huanggang Daily Chemical and Tian'an Daily Chemical [1] - The merger does not require submission for shareholder meeting approval [1]

Group 1 - The core point of the article is that Yong'an Pharmaceutical announced a temporary board meeting to discuss a merger involving its subsidiary, which will lead to changes in investment targets and related transactions [1] - For the first half of 2025, Yong'an Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 64.14%, health food accounts for 24.67%, chemical manufacturing accounts for 10.88%, and other businesses account for 0.32% [1] - As of the report, Yong'an Pharmaceutical has a market capitalization of 5.3 billion yuan [1] Group 2 - Prior to the arrest of the chairman of Peking University Pharmaceutical, police had investigated the group's factory premises, indicating potential issues within the company [1] - Internal sources suggest that the group's assets have been disposed of by the chairman, with significant amounts of funds unaccounted for [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) is consolidating resources and improving efficiency by merging its subsidiary Huanggang Yong'an Daily Chemical Co., Ltd. into its wholly-owned subsidiary Hubei Tian'an Daily Chemical Co., Ltd. [1] Group 1: Merger Details - The merger will result in Tian'an Daily Chemical being the surviving entity, while Huanggang Daily Chemical will be dissolved [1] - The merger does not involve any cash payments; shareholders of Huanggang Daily Chemical will exchange their shares for equity in Tian'an Daily Chemical on a pro-rata basis [1] - After the merger, all assets, liabilities, and equity of Huanggang Daily Chemical will be legally inherited by Tian'an Daily Chemical [1] Group 2: Investment Implications - The company's previous investment of 30 million yuan in Huanggang Daily Chemical will be converted into a direct investment in Tian'an Daily Chemical [1] - The shareholding ratio will remain unchanged, with the company directly holding 6.5217% of Tian'an Daily Chemical's equity post-merger [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-66 潜江永安药业股份有限公司 关于参股公司黄冈日化拟被其全资子公司吸收合并 导致投资标的发生变更暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 为整合资源、提高效率、降低成本，潜江永安药业股份有限公司（以下简称 "公司"）参股公司黄冈永安日用化工有限公司（以下简称"黄冈日化"）拟被 其全资子公司湖北天安日用化工有限公司（以下简称"天安日化"）吸收合并， 以天安日化为合并存续方，黄冈日化为被合并方。本次吸收合并不涉及现金收付， 黄冈日化各股东将以其原持有的黄冈日化股权所对应的权益，通过换股方式等比 例转为直接持有天安日化的股权。合并完成后，黄冈日化将予以注销，其全部资 产、负债、权益等由天安日化依法承继。公司原对黄冈日化 3,000 万元投资将转 变为公司对天安日化的投资，持股比例将由间接持有天安日化 6.5217%的股权转 为直接持有天安日化 6.5217%的股权。 公司控股股东及实际控制人陈勇先生系黄冈永安药业股份有限公司（以下简 称"黄冈永安"）、黄冈日化 ...

表决结果：以同意 5 票，反对 0 票，弃权 0 票，回避表决 2 票。关联董 事陈勇先生、陈子笛先生回避了对本项议案的表决。 董事会同意参股公司黄冈日化被其全资子公司吸收合并，合并完成后，黄冈 日化将予以注销，其全部资产、负债、权益由天安日化依法承继。本次吸收合并 不涉及现金收付，黄冈日化各股东将以其原持有的黄冈日化股权所对应的权益， 通过换股方式等比例转为直接持有天安日化的股权。公司原对黄冈日化 3,000 万元投资将转变为公司对天安日化的投资，持股比例将由间接持有天安日化 6.5217%的股权转为直接持有天安日化 6.5217%的股权。 第七届董事会第十一次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）第七届董事会第十一次临 时会议的会议通知于 2025 年 11 月 7 日以书面、电话、传真、电子邮件等形式送 达公司全体董事，会议于 2025 年 11 月 11 日在公司会议室以通讯方式召开，本 次会议应参与审议表决董事 7 人，实际参与审议表决董事 7 人。本次会议由公 司董事长陈勇先生 ...